Outputs (14)

Assessing the androgenic and metabolic heterogeneity in polycystic ovary syndrome using cluster analysis (2022)
Journal Article
Deshmukh, H., Akbar, S., Bhaiji, A., Saeed, Y., Shah, N., Adeleke, K., …Sathyapalan, T. (2023). Assessing the androgenic and metabolic heterogeneity in polycystic ovary syndrome using cluster analysis. Clinical Endocrinology, 98(3), 400-406. https://doi.org/10.1111/cen.14847

Introduction: Some but not all women with polycystic ovary syndrome (PCOS) develop the metabolic syndrome (MS). The objective of this study was to determine if a subset of women with PCOS had higher androgen levels predisposing them to MS and whether... Read More about Assessing the androgenic and metabolic heterogeneity in polycystic ovary syndrome using cluster analysis.

Genetic risk for the polycystic ovary syndrome, bone mineral density and fractures in women and men: A UK Biobank Mendelian randomisation study (2021)
Journal Article
Deshmukh, H., Shah, N., Papageorgiou, M., Abdalla, M. A., Lhaf, F., Aye, M., & Sathyapalan, T. (2022). Genetic risk for the polycystic ovary syndrome, bone mineral density and fractures in women and men: A UK Biobank Mendelian randomisation study. Bone, 155, Article 116285. https://doi.org/10.1016/j.bone.2021.116285

Introduction: There is conflicting data on the effect of polycystic ovary syndrome (PCOS) on bone mineral density (BMD) and fracture risk. Recent genetic data suggest that men may also carry genetic risk factors for PCOS; the associations of these fa... Read More about Genetic risk for the polycystic ovary syndrome, bone mineral density and fractures in women and men: A UK Biobank Mendelian randomisation study.

Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis (2020)
Journal Article
Deshmukh, H., Papageorgiou, M., Aye, M., England, J., Abdalla, M., & Sathyapalan, T. (in press). Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis. Clinical Endocrinology, https://doi.org/10.1111/cen.14330

Introduction
Untreated hyperthyroidism is associated with accelerated bone turnover, low bone mineral density (BMD) and increased susceptibility to fragility fractures. Although treatment appears to improve or even reverse some of these adverse skel... Read More about Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis.

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome (2020)
Journal Article
Javed, Z., Papageorgiou, M., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2020). The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome. Endocrine Connections, 9(6), 563-569. https://doi.org/10.1530/EC-20-0173

Context: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managin... Read More about The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome.

Is weight loss harmful for skeletal health in obese older adults? (2019)
Journal Article
Papageorgiou, M., Kerschan-Schindl, K., Sathyapalan, T., & Pietschmann, P. (2020). Is weight loss harmful for skeletal health in obese older adults?. Gerontology, 66(1), 2-14. https://doi.org/10.1159/000500779

Purpose of Review: In view of the existing uncertainty about the implications of intentional weight loss in older obese adults, the present review (a) summarizes the available evidence from epidemiological and interventional studies concerning the ef... Read More about Is weight loss harmful for skeletal health in obese older adults?.

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical Endocrinology, 90(6), 805-813. https://doi.org/10.1111/cen.13968

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascu... Read More about Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study.

A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Kilpatrick, E., Mann, V., Corless, L., Abouda, G., Rigby, A. S., Atkin, S., & Sathyapalan, T. (2019). A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients, 11(1), 188. https://doi.org/10.3390/nu11010188

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemis... Read More about A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome.

Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome (PCOS) (2018)
Journal Article
Deshmukh, H., Papageorgiou, M., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (in press). Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome (PCOS). Clinical Endocrinology, 90(1), 162-169. https://doi.org/10.1111/cen.13879

Objective
The aim of this study was to develop a simple phenotypic algorithm that can capture the underlying clinical and hormonal abnormalities to help in the diagnosis and risk stratification of polycystic ovary syndrome (PCOS).

Methods
The study... Read More about Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome (PCOS).

Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women (2018)
Journal Article
Papageorgiou, M., Sathyapalan, T., & Schutte, R. (2019). Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women. Journal of Cachexia, Sarcopenia and Muscle, 10(1), 131-139. https://doi.org/10.1002/jcsm.12359

© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders Background: Despite several muscle mass measures being used in the current defi... Read More about Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women.

Effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes (2018)
Journal Article
Al-Qaissi, A., Papageorgiou, M., Deshmukh, H., Madden, L. A., Rigby, A., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019). Effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 21(3), 533-540. https://doi.org/10.1111/dom.13548

Aims
Endothelial microparticles (EMPs) are novel surrogate markers of endothelial injury and dysfunction that may be differentially produced in response to acute insulin‐induced hypoglycaemia in adults with and without type 2 diabetes.